comscoreExperimental Elacestrant: A Standard of Care for Pre-Treated, Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer?

Experimental Elacestrant: A Standard of Care for Pre-Treated, Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer?

Dr. Aditya Bardia discusses results from the EMERALD trial.
Dec 11, 2021
00:00
Download
00:00

At the 2021 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia presented results from the EMERALD trial, comparing the experimental medicine elacestrant to the standard of care for post-menopausal women diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy. That standard of care is either Faslodex or an aromatase inhibitor.

Listen to the podcast to hear Dr. Bardia explain:

  • how elacestrant works

  • the results of the EMERALD study

  • what the results mean for post-menopausal women and men diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that has grown while being treated with hormonal therapy



About the guest
 
Aditya Bardia, MD, MPH

Dr. Aditya Bardia is associate professor of medicine at Harvard Medical School and director of the breast cancer research program at Massachusetts General Hospital Cancer Center.



— Last updated on February 11, 2022, 7:58 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate